Medtech Insight is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

FDA Chief Counsel Addresses Staff Turnover, Device Bans

This article was originally published in The Gray Sheet

Executive Summary

Staff turnover in FDA's Office of the Chief Counsel is a positive, says the agency's top lawyer Elizabeth Dickinson. The chief counsel also discussed recent device bans, off-label communication policy efforts and the agency’s ongoing transparency initiative at the annual Food & Drug Law Institute conference.


Related Content

Public Supports US FDA Ban On Electroshock Devices
In Case You Missed It: Top 10 Gray Sheet Stories In May
Vascular Solutions Case (Partially) Points Way Forward For Off-Label Marketing
Illness Risk Fuels FDA Ban On Powdered Surgical Gloves
FDA Unveils Plan To Boost Transparency To Industry